Demographics, baseline characteristics, and outcomes of patients with IRD admitted to hospital due to severe SARS-CoV-2 infection.
| Hospitalized, n = 41 | Hospitalized and Surviving, n = 31 | Hospitalized and Deceased, n = 10 | P* | |
|---|---|---|---|---|
| Age, yrs, median (range) | 72 (36–87) | 72 (36–84) | 76 (61–87) | 0.06 |
| Female | 25 (61) | 20 (64) | 5 (50) | 0.41 |
| Hospital stay, days, median | 9 | 9 | 9 | 0.88 |
| Deaths | 10 (24) | 0 (0) | 10 (100) | |
| Comorbidities | ||||
| Hypertension | 23 (56) | 17 (54) | 6 (60) | 0.77 |
| Lung diseasea | 14 (34) | 8 (25) | 6 (60) | 0.04 |
| Diabetes | 9 (22) | 6 (19) | 3 (30) | 0.47 |
| Cardiovascular disease | 7 (17) | 4 (13) | 3 (30) | 0.21 |
| Malignant tumor | 5 (12) | 3 (10) | 2 (20) | 0.38 |
| Other comorbidities | 9 (22) | 5 (16) | 4 (40) | 0.11 |
| None | 6 (15) | 6 (19) | 0 | 0.13 |
| Rheumatic disease | ||||
| RA | 16 (39) | 12 (39) | 4 (40) | 0.94 |
| SpA | 3 (7) | 3 (10) | 0 | 0.30 |
| PsA | 4 (10) | 4 (13) | 0 | 0.23 |
| SLE | 4 (10) | 2 (6) | 2 (20) | 0.20 |
| Sjögren syndrome | 4 (10) | 4 (13) | 0 | 0.23 |
| Vasculitis | 3 (7) | 1 (3) | 2 (20) | 0.07 |
| Inflammatory myopathy | 1 (2) | 1 (3) | 0 | 0.56 |
| PMR | 6 (15) | 4 (13) | 2 (20) | 0.58 |
| Active IRDb | 6 (15) | 3 (10) | 3 (30) | 0.11 |
| Disease duration, yrs, median | 15 | 12 | 18 | 0.45 |
| IRD treatment | ||||
| No DMARDs | 10 (24) | 6 (19) | 4 (40) | 0.18 |
| Conventional synthetic DMARDsc | 23 (56) | 19 (61) | 4 (40) | 0.23 |
| Biologic DMARDs | 12 (29) | 9 (29) | 3 (30) | 0.95 |
| Anti-TNF | 4 (10) | 4 (13) | 0 | 0.23 |
| RTX | 7 (17) | 4 (13) | 3 (30) | 0.21 |
| ABA | 1 (2) | 1 (3) | 0 | 0.56 |
| JAK inhibitors | 1 (2) | 1 (3) | 0 | 0.56 |
| GC use | 27 (66) | 18 (58) | 9 (90) | 0.06 |
| GC dose, mg, mean | 5.2 | 5.4 | 4.6 | 0.54 |
Values are expressed as n (%) unless otherwise indicated. Values in bold are statistically significant.
↵a Lung disease included interstitial lung disease, chronic obstructive pulmonary disease, asthma, or smoking.
↵b Active rheumatic disease included high clinical activity, or newly diagnosed or recently started biologics treatment.
↵c Conventional synthetic DMARDs included methotrexate, hydroxychloroquine, sulfasalazine, leflunomide, azathioprine, and mycophenolate mofetil.
↵* Comparisons were between surviving and deceased patients. ABA: abatacept; DMARD: disease-modifying antirheumatic drug; GC: glucocorticoid; IRD: inflammatory rheumatic disease; JAK: Janus kinase; PMR: polymyalgia rheumatica; PsA: psoriatic arthritis; RA: rheumatoid arthritis; RTX: rituximab; SLE: systemic lupus erythematosus; SpA: spondyloarthritis; TNF: tumor necrosis factor.